<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK547989" /><meta name="ncbi_domain" content="livertox" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK547989/" /><meta name="ncbi_pagename" content="Vinca Alkaloids - LiverTox - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Vinca Alkaloids - LiverTox - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.15.2/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.15.2/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]" /><meta name="citation_title" content="Vinca Alkaloids" /><meta name="citation_publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="citation_date" content="2020/09/12" /><meta name="citation_pmid" content="31643321" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK547989/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Vinca Alkaloids" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="National Institute of Diabetes and Digestive and Kidney Diseases" /><meta name="DC.Date" content="2020/09/12" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK547989/" /><meta name="description" content="The vinca alkaloids include vincristine, vinblastine and vinorelbine which are important antineoplastic agents used in many chemotherapeutic regimens for a wide variety of cancers. Despite their cytotoxic activity against cancer cells, the vinca alkaloids have rarely been implicated in causing clinically apparent acute liver injury." /><meta name="og:title" content="Vinca Alkaloids" /><meta name="og:type" content="book" /><meta name="og:description" content="The vinca alkaloids include vincristine, vinblastine and vinorelbine which are important antineoplastic agents used in many chemotherapeutic regimens for a wide variety of cancers. Despite their cytotoxic activity against cancer cells, the vinca alkaloids have rarely been implicated in causing clinically apparent acute liver injury." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK547989/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/livertox/VincaAlkaloids/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK547989/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE88715C0468AF910000000002FD00DE.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="protfam">Protein Family Models</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All Drug Records" href="/books/n/livertox/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-livertox-lrg.png" alt="Cover of LiverTox" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK547989_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK547989_dtls__"><div>Bethesda (MD): <a href="https://www.niddk.nih.gov/" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">National Institute of Diabetes and Digestive and Kidney Diseases</a>; 2012-.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/livertox/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search this book" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search this book" submit="false" style="padding: 0.1em 0.4em;" /></div></form></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Vilazodone/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Vismodegib/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK547989_"><span class="title" itemprop="name">Vinca Alkaloids</span></h1><p class="small">Last Update: <span itemprop="dateModified">September 12, 2020</span>.</p></div><div class="body-content whole_rhythm" itemprop="text"><p>VINBLASTINE, VINCRISTINE, VINORELBINE</p><div id="VincaAlkaloids.OVERVIEW"><h2 id="_VincaAlkaloids_OVERVIEW_">OVERVIEW</h2><div id="VincaAlkaloids.Introduction"><h3>Introduction</h3><p>The vinca alkaloids include vincristine, vinblastine and vinorelbine which are important antineoplastic agents used in many chemotherapeutic regimens for a wide variety of cancers. Despite their cytotoxic activity against cancer cells, the vinca alkaloids have rarely been implicated in causing clinically apparent acute liver injury.</p></div><div id="VincaAlkaloids.Background"><h3>Background</h3><p>The vinca alkaloids are antineoplastic agents that act by binding to intracellular tubulin, the basic protein subunit of microtubules which are important in many intracellular processes including mitosis and cell division. The vinca alkaloids inhibit cell division by blocking mitosis; they also inhibit purine and RNA synthesis causing death of rapidly dividing cells. Vincristine and vinblastine were initially isolated from periwinkle (vinca rosea), extracts of which were found to have antitumor activity. Subsequently, they have been synthesized, although their structure is quite complex. Vinorelbine is a semisynthetic derivative of extracts of periwinkle. Vincristine (vin kris' teen) was approved for use in cancer chemotherapy in 1963, vinblastine (vin blas' teen) in 1965 and vinrelbine (vin or' el been) in 1994. Vincristine and vinblastine have become major components of many combination anticancer regimens, used particularly in treatment of acute leukemia, Hodgkin disease and other lymphomas, various sarcomas, Wilms tumor, neuroblastoma, and breast and lung cancer. Vinorelbine has had a more restricted use and is approved only for advance non-small cell lung cancer. The vinca alkaloids are given intravenously, typically at one or two week intervals in cycles with other agents. Importantly, the vinca alkaloids should only be given intravenously; if given intrathecally, they cause a progressive neurological syndrome, ascending paralysis and death. The vinca alkaloids are available in generic forms and under the trade names Oncovin (vincristine), Velban (vinblastine) and Navelbine (vinorelbine). Side effects are common and include nausea, vomiting, fatigue, headache, dizziness, peripheral neuropathy, hoarseness, ataxia, dysphagia, urinary retention, constipation, diarrhea, bone marrow suppression, alopecia and phlebitis at the infusion site. Uncommon but potential severe adverse events include severe neutropenia, bleeding, peripheral neuropathy, pulmonary toxicity, hypersensitivity reactions and embryo-fetal toxicity.</p></div><div id="VincaAlkaloids.Hepatotoxicity"><h3>Hepatotoxicity</h3><p>Despite being cytotoxic for cancer cells and metabolized actively by the liver, the vinca alkaloids have only rarely been associated with significant hepatic toxicity. Because they are usually given with other anticancer agents and/or radiotherapy, which may also be hepatotoxic, the role that they play in causing liver injury is not always clear. When given on their own, the vinca alkaloids are associated with transient and asymptomatic elevations in serum aminotransferase levels in 5% to 10% of patients. However, clinically apparent liver injury attributed to the vinca alkaloids has been rare and not well defined. Both vincristine and vinblastine may increase the risk of sinusoidal obstruction syndrome, also known as venoocclusive disease of the liver, caused by radiation, dactinomycin or the alkylating agents, but not when given on their own. In these situations, the risk of sinusoidal obstruction syndrome is greater with higher doses of radiation, dactinomycin or cyclophosphamide and younger age (in children).</p><p>Likelihood score, vincristine: C (probable rare cause of clinically apparent liver injury).</p><p>Likelihood score, vinblastine: E* (unproven but suspected rare cause of clinically apparent liver injury)</p><p>Likelihood score, vinorelbine: E* (unproven but suspected rare cause of clinically apparent liver injury).</p></div><div id="VincaAlkaloids.Mechanism_of_Injury"><h3>Mechanism of Injury</h3><p>The reason why the vinca alkaloids are not particularly toxic to liver cells is not known, but cell division and mitosis (the major targets of vincristine and vinblastine) are rare in the resting liver. Both agents are extensively metabolized in the liver and excreted in bile.</p></div><div id="VincaAlkaloids.Outcome_and_Management"><h3>Outcome and Management</h3><p>Serum enzyme elevations are not uncommon during cancer chemotherapy and may occasionally be dose limiting; however, the vinca alkaloids are rarely the sole or major reason for significant or persistent enzyme elevations or clinically apparent liver injury. Patients who develop sinusoidal obstruction syndrome, but recover, can be safely treated with further courses of vincristine alone or combined with reduced doses of the alkylating agent or dactinomycin.</p><p>Drug Class: <a href="/books/n/livertox/AntineoplasticAgents/">Antineoplastic Agents</a></p></div></div><div id="VincaAlkaloids.CASE_REPORT"><h2 id="_VincaAlkaloids_CASE_REPORT_">CASE REPORT</h2><div id="VincaAlkaloids.Case_1_Fatal_sinusoidal_o"><h3>Case 1. Fatal sinusoidal obstruction syndrome after abdominal irradiation and vincristine therapy.(<a class="bk_pop" href="#VincaAlkaloids.REF.1">1</a>)</h3><p>A 30 year old woman with poorly differentiated lymphocytic nodular lymphoma was treated with prednisone and weekly infusions of vincristine and once weekly oral streptonigrin (an antibiotic and bioreductive antineoplastic agent). Vincristine was withdrawn after 4 cycles because of neuropathy. After 6 cycles of chemotherapy, she underwent mediastinal (2000 rads) and abdominal (2225 rads) irradiation over a two month period with another cycle of vincristine (day 88). On day 111, which was 10 days after finishing radiation therapy and 33 days after the fifth and last infusion of vincristine, she developed pancytopenia, fever, abdominal pain, ascites and jaundice. Serum aminotransferase levels were markedly elevated with only modest increases in alkaline phosphatase. The fever and pancytopenia resolved with antibiotic therapy, but she developed progressive jaundice and hepatic failure and died 4 weeks later. Autopsy showed an enlarged, congested liver with sinusoidal obstruction and severe centrilobular necrosis. The autopsy showed no residual evidence of lymphoma.</p><div id="VincaAlkaloids.Key_Points"><h4>Key Points</h4><div id="VincaAlkaloids.Tc" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK547989/table/VincaAlkaloids.Tc/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__VincaAlkaloids.Tc_lrgtbl__"><table><tbody><tr><th id="hd_b_VincaAlkaloids.Tc_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Medication:</th><td headers="hd_b_VincaAlkaloids.Tc_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Vincristine, hepatic irradiation</td></tr><tr><th id="hd_b_VincaAlkaloids.Tc_1_1_2_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Pattern:</th><td headers="hd_b_VincaAlkaloids.Tc_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Hepatocellular (R=~100)</td></tr><tr><th id="hd_b_VincaAlkaloids.Tc_1_1_3_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Severity:</th><td headers="hd_b_VincaAlkaloids.Tc_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">5+ (hepatic failure and death)</td></tr><tr><th id="hd_b_VincaAlkaloids.Tc_1_1_4_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.latency/">Latency</a>:</th><td headers="hd_b_VincaAlkaloids.Tc_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">111 days after starting vincristine, 10 days after irradiation</td></tr><tr><th id="hd_b_VincaAlkaloids.Tc_1_1_5_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Recovery:</th><td headers="hd_b_VincaAlkaloids.Tc_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">None</td></tr><tr><th id="hd_b_VincaAlkaloids.Tc_1_1_6_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Other medications:</th><td headers="hd_b_VincaAlkaloids.Tc_1_1_6_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Prednisone, streptonigrin</td></tr></tbody></table></div></div></div><div id="VincaAlkaloids.Laboratory_Values"><h4>Laboratory Values</h4><div id="VincaAlkaloids.Td" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK547989/table/VincaAlkaloids.Td/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__VincaAlkaloids.Td_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_VincaAlkaloids.Td_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Days After<br />Starting</th><th id="hd_h_VincaAlkaloids.Td_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Chemo<br />Therapy</th><th id="hd_h_VincaAlkaloids.Td_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.alanine-aminotransferase-alt-/">ALT</a><br />(U/L)</th><th id="hd_h_VincaAlkaloids.Td_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Alk P<br />(U/L)</th><th id="hd_h_VincaAlkaloids.Td_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.bilirubin/">Bilirubin</a><br />(mg/dL)</th><th id="hd_h_VincaAlkaloids.Td_1_1_1_6" scope="col" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">Comments</th></tr></thead><tbody><tr><td headers="hd_h_VincaAlkaloids.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">1</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_2 hd_h_VincaAlkaloids.Td_1_1_1_3 hd_h_VincaAlkaloids.Td_1_1_1_4 hd_h_VincaAlkaloids.Td_1_1_1_5 hd_h_VincaAlkaloids.Td_1_1_1_6" colspan="5" rowspan="1" style="text-align:center;vertical-align:top;">Started oral prednisone and weekly doses of vincristine and streptonigrin</td></tr><tr><td headers="hd_h_VincaAlkaloids.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">11</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">V &#x00026; S</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">9</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">105</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">0.8</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_VincaAlkaloids.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">17</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">V &#x00026; S</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">10</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">100</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_VincaAlkaloids.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">24</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">V &#x00026; S</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">11</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">105</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_VincaAlkaloids.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">31</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">S</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">13</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">90</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_VincaAlkaloids.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">38</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">S</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">11</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">90</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_VincaAlkaloids.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">53</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Rad</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">15</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">135</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_VincaAlkaloids.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">88</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Rad &#x00026; V</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">25</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">140</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_VincaAlkaloids.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">111</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Admission</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">4000</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">255</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">5.8</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a class="def" href="/books/n/livertox/glossary/def-item/glossary.jaundice/">Jaundice</a>, ascites, fever</td></tr><tr><td headers="hd_h_VincaAlkaloids.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">113</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Day 2</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">1550</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">230</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">6.0</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_VincaAlkaloids.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">117</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Day 6</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">185</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">265</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">10.0</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_VincaAlkaloids.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">122</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Day 11</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">88</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">405</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">20.0</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_VincaAlkaloids.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">131</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Day 20</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">62</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">340</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;">20.5</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr><tr><td headers="hd_h_VincaAlkaloids.Td_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">141</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Day 30</td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_3 hd_h_VincaAlkaloids.Td_1_1_1_4 hd_h_VincaAlkaloids.Td_1_1_1_5 hd_h_VincaAlkaloids.Td_1_1_1_6" colspan="4" rowspan="1" style="text-align:center;vertical-align:top;">Died of hepatic failure</td></tr><tr><td headers="hd_h_VincaAlkaloids.Td_1_1_1_1 hd_h_VincaAlkaloids.Td_1_1_1_2" colspan="2" scope="row" rowspan="1" style="text-align:center;vertical-align:top;"><b>Normal Values</b></td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;30</b></td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;275</b></td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_5" rowspan="1" colspan="1" style="text-align:center;vertical-align:top;"><b>&#x0003c;1.2</b></td><td headers="hd_h_VincaAlkaloids.Td_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>* </dt><dd><div id="VincaAlkaloids.TF.d.1"><p class="no_margin">Abbreviations: Rad=radiation therapy, S=oral streptonigrin, V=vincristine infusion.</p></div></dd></dl></div></div></div></div><div id="VincaAlkaloids.Comment"><h4>Comment</h4><p>The clinical presentation with weight gain, abdominal pain, ascites and jaundice is typical of sinusoidal obstruction syndrome. Hepatic irradiation, dactinomycin, and the alkylating agents (dacarbazine, cyclophosphamide, myleran and busulfan) are most frequently associated with this form of liver injury. The injury is probably due to direct toxicity to sinusoidal lining cells with their subsequent necrosis and extrusion into the sinusoidal spaces, which causes obstruction, hemorrhage and local ischemia to hepatocytes. Signs of portal hypertension appear early, followed (in severe cases) by jaundice and hepatic failure. The dose of radiation used in this patient (&#x0003c;3000 rads) was not considered adequate to cause sinusoidal obstruction syndrome on its own, which suggested that vincristine might have increased the risk of this complication.</p></div></div></div><div id="VincaAlkaloids.PRODUCT_INFORMATION"><h2 id="_VincaAlkaloids_PRODUCT_INFORMATION_">PRODUCT INFORMATION</h2><p><b>REPRESENTATIVE TRADE NAMES</b></p><p>Vinblastine &#x02013; Generic, Velban&#x000ae;</p><p>Vincristine &#x02013; Generic, Oncovin&#x000ae;</p><p>Vinorelbine &#x02013; Generic, Navelbine&#x000ae;</p><p><b>DRUG CLASS</b></p><p>Antineoplastic Agents</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=vinblastine" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a> (Vinblastine)</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=vincristine" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a> (Vincristine)</p><p><a href="https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&#x00026;query=vinorelbine" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">COMPLETE LABELING</a> (Vinorelbine)</p><p>Product labeling at DailyMed, National Library of Medicine, NIH</p></div><div id="VincaAlkaloids.CHEMICAL_FORMULAS_AND_STR"><h2 id="_VincaAlkaloids_CHEMICAL_FORMULAS_AND_STR_">CHEMICAL FORMULAS AND STRUCTURES</h2><div id="VincaAlkaloids.Te" class="table"><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK547989/table/VincaAlkaloids.Te/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__VincaAlkaloids.Te_lrgtbl__"><table><thead><tr><th id="hd_h_VincaAlkaloids.Te_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">DRUG</th><th id="hd_h_VincaAlkaloids.Te_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">CAS REGISTRY NUMBER</th><th id="hd_h_VincaAlkaloids.Te_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">MOLECULAR FORMULA</th><th id="hd_h_VincaAlkaloids.Te_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">STRUCTURE</th></tr></thead><tbody><tr><td headers="hd_h_VincaAlkaloids.Te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Vinblastine</td><td headers="hd_h_VincaAlkaloids.Te_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134980402" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">865-21-4</a></td><td headers="hd_h_VincaAlkaloids.Te_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C46-H58-N4-O9</td><td headers="hd_h_VincaAlkaloids.Te_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134980402" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=134980402" alt="image 134980402 in the ncbi pubchem database" /></a></td></tr><tr><td headers="hd_h_VincaAlkaloids.Te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Vincristine</td><td headers="hd_h_VincaAlkaloids.Te_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134970704" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">57-22-7</a></td><td headers="hd_h_VincaAlkaloids.Te_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C46-H56-N4-O10</td><td headers="hd_h_VincaAlkaloids.Te_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/134970704" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=134970704" alt="image 134970704 in the ncbi pubchem database" /></a></td></tr><tr><td headers="hd_h_VincaAlkaloids.Te_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Vinorelbine</td><td headers="hd_h_VincaAlkaloids.Te_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135049333" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem">71486-22-1</a></td><td headers="hd_h_VincaAlkaloids.Te_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">C45-H54-N4-O8</td><td headers="hd_h_VincaAlkaloids.Te_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;"><a href="https://pubchem.ncbi.nlm.nih.gov/substance/135049333" title="View this structure in PubChem" class="img_link" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubchem"><img src="https://pubchem.ncbi.nlm.nih.gov/image/imgsrv.fcgi?t=l&amp;sid=135049333" alt="image 135049333 in the ncbi pubchem database" /></a></td></tr></tbody></table></div></div></div><div id="VincaAlkaloids.CITED_REFERENCE"><h2 id="_VincaAlkaloids_CITED_REFERENCE_">CITED REFERENCE</h2><dl class="temp-labeled-list"><dt>1.</dt><dd><div class="bk_ref" id="VincaAlkaloids.REF.1">Hansen MM, Ranek L, Walbom S, Nissen NI. Fatal hepatitis following irradiation and vincristine. <span><span class="ref-journal">Acta Med Scand. </span>1982;<span class="ref-vol">212</span>:171–4.</span> [<a href="/pubmed/7148508" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7148508</span></a>]</div></dd></dl></div><div id="VincaAlkaloids.ANNOTATED_BIBLIOGRAPHY"><h2 id="_VincaAlkaloids_ANNOTATED_BIBLIOGRAPHY_">ANNOTATED BIBLIOGRAPHY</h2><p>References updated: 12 September 2020</p><p>Abbreviations: ABVD, doxorubicin, bleomycin, vinblastine and dacarbazine; BEACOPP, bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone; CHOP, chemotherapy regimen of cyclophosphamide, doxorubicin, vincristine and prednisone; G-CHOP, obinutuzumab with CHOP; R-CHOP, rituximab with CHOP; <a class="def" href="/books/n/livertox/glossary/def-item/glossary.sinusoidalobstruction-syndrome-sos-/">SOS</a>, sinusoidal obstruction syndrome.</p><ul class="first-line-outdent"><li><div class="bk_ref" id="VincaAlkaloids.REF.zimmerman.1999">Zimmerman HJ. The vinca alkaloids. Oncotherapeutic and immunosuppressive agents. In, Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott, 1999, pp. 692-4.<div><i>(Expert review of hepatotoxicity published in 1999 mentions that vincristine and vinblastine appear to cause little hepatic injury in humans or experimental animals).</i></div></div></li><li><div class="bk_ref" id="VincaAlkaloids.REF.deleve.2013">DeLeve LD. Cancer chemotherapy. In, Kaplowitz N, DeLeve LD, eds. Drug-induced liver disease. 3rd ed. Amsterdam: Elsevier, 2013, pp. 549-68.<div><i>(Review of hepatotoxicity of published in 2007; mentions that vincristine may increase the risk of sinusoidal obstruction syndrome caused by dactinomycin).</i></div></div></li><li><div class="bk_ref" id="VincaAlkaloids.REF.chabner.2011">Chabner BA, Bertino J, Clearly J, Ortiz T, Lane A, Supko JG, Ryan DP. Cytotoxic agents. Chemotherapy of neoplastic diseases. In, Brunton LL, Chabner BA, Knollman BC, eds. Goodman &#x00026; Gilman's the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011, pp. 1677-730.<div><i>(Textbook of pharmacology and therapeutics).</i></div></div></li><li><div class="bk_ref" id="VincaAlkaloids.REF.costa.1962.39">Costa G, Hreshchyshyn MM, Holland JF. Initial clinical studies with vincristine. <span><span class="ref-journal">Cancer Chemother Rep. </span>1962;<span class="ref-vol">24</span>:39–44.</span> [<a href="/pubmed/14023264" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 14023264</span></a>]<div><i>(Preliminary studies of vincristine against various cancers; dose limiting side effects included peripheral neuropathy and bone marrow suppression; 5 of 12 patients had patchy hepatic necrosis on autopsy despite having no abnormalities of liver tests before death).</i></div></div></li><li><div class="bk_ref" id="VincaAlkaloids.REF.bohannon.1963.613">Bohannon RA, Miller DG, Diamond HD. Vincristine in the treatment of lymphomas and leukemias. <span><span class="ref-journal">Cancer Res. </span>1963;<span class="ref-vol">23</span>:613–21.</span> [<a href="/pubmed/13968454" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 13968454</span></a>]<div><i>(Review of mechanism of action, clinical efficacy and toxicity of vincristine; AST elevations occurred in a small proportion of patients, but were not dose-limiting).</i></div></div></li><li><div class="bk_ref" id="VincaAlkaloids.REF.raine.1991.268">Raine J, Bowman A, Wallendszus K, Pritchard J. Hepatopathy-thrombocytopenia syndrome&#x02013;a complication of dactinomycin therapy for Wilms' tumor: a report from the United Kingdom Childrens Cancer Study Group. <span><span class="ref-journal">J Clin Oncol. </span>1991;<span class="ref-vol">9</span>:268–73.</span> [<a href="/pubmed/1846405" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1846405</span></a>]<div><i>(Among 355 children with Wilms tumor who received the combination of dactinomycin and vincristine, 5 developed &#x0201c;hepatopathy-thrombocytopenia syndrome&#x0201d; [bilirubin 1.3-6.1 mg/dL, ALT 335-5723 U/L], but none of 146 given vincristine alone developed this syndrome).</i></div></div></li><li><div class="bk_ref" id="VincaAlkaloids.REF.hansen.1982.171">Hansen MM, Ranek L, Walbom S, Nissen NI. Fatal hepatitis following irradiation and vincristine. <span><span class="ref-journal">Acta Med Scand. </span>1982;<span class="ref-vol">212</span>:171–4.</span> [<a href="/pubmed/7148508" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7148508</span></a>]<div><i>(30 year old woman with lymphoma developed SOS after liver irradiation and chemotherapy with vincristine [bilirubin 6.0 rising to 21.0 mg/dL, AST 4000 U/L, Alk P 250 U/L], with progressive multiorgan failure and death 4 weeks later: Case 1).</i></div></div></li><li><div class="bk_ref" id="VincaAlkaloids.REF.el_saghir.1984.2006">el Saghir NS, Hawkins KA. Hepatotoxicity following vincristine therapy. <span><span class="ref-journal">Cancer. </span>1984;<span class="ref-vol">54</span>:2006–8.</span> [<a href="/pubmed/6090004" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 6090004</span></a>]<div><i>(49 year old woman with lung cancer treated with VP-16, cyclophosphamide and vincristine developed ALT elevations [2 to 6 times ULN] a week after chemotherapy with normal bilirubin levels and liver biopsy; ALT elevations recurred when vincristine was given alone).</i></div></div></li><li><div class="bk_ref" id="VincaAlkaloids.REF.green.1988.270">Green DM, Finklestein JZ, Norkool P, D'Angio GJ. Severe hepatic toxicity after treatment with single-dose dactinomycin and vincristine. A report of the National Wilms' Tumor Study. <span><span class="ref-journal">Cancer. </span>1988;<span class="ref-vol">62</span>:270–3.</span> [<a href="/pubmed/2838151" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2838151</span></a>]<div><i>(5 children, ages 1 to 8 years, developed severe hepatic injury [SOS] 2-9 days after the 2nd or 3rd course of dactinomycin and vincristine, and 1 died; no recurrence when vincristine was restarted alone or with reduced and split doses of dactinomycin).</i></div></div></li><li><div class="bk_ref" id="VincaAlkaloids.REF.green.1990.1525">Green DM, Norkool P, Breslow NE, Finklestein JZ, D'Angio GJ. Severe hepatic toxicity after treatment with vincristine and dactinomycin using single-dose or divided-dose schedules: a report from the National Wilms' Tumor Study. <span><span class="ref-journal">J Clin Oncol. </span>1990;<span class="ref-vol">8</span>:1525–30.</span> [<a href="/pubmed/2167951" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2167951</span></a>]<div><i>(Retrospective analysis of 154 children with Wilms tumor treated with dactinomycin and vincristine found higher rate of hepatotoxicity with higher single dose dactinomycin [14%] than with lower [4%] or split doses [3%]; clinical presentation with ascites, elevated AST [529 to 8208 U/L] and 50% with jaundice).</i></div></div></li><li><div class="bk_ref" id="VincaAlkaloids.REF.zhou.1992.1">Zhou XJ, Rahmani R. Preclinical and clinical pharmacology of vinca alkaloids. <span><span class="ref-journal">Drugs. </span>1992;<span class="ref-vol">44</span> Suppl 4:1–16.</span> [<a href="/pubmed/1283846" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1283846</span></a>]<div><i>(Review of structure, mechanism of action, pharmacology, clinical efficacy and toxicities of vinca alkaloids; hepatotoxicity not discussed).</i></div></div></li><li><div class="bk_ref" id="VincaAlkaloids.REF.bisogno.1997.245">Bisogno G, de Kraker J, Weirich A, Masiero L, Ludwig R, Tournade MF, Carli M. Veno-occlusive disease of the liver in children treated for Wilms tumor. <span><span class="ref-journal">Med Pediatr Oncol. </span>1997;<span class="ref-vol">29</span>:245–51.</span> [<a href="/pubmed/9251728" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9251728</span></a>]<div><i>(Among 511 children with Wilms tumor treated with dactinomycin and vincristine with or without other agents or irradiation, 64 [12%] had hepatotoxicity including 41 [8%] with SOS [all with hepatomegaly, 83% ascites, 28% jaundice, 6% fatal]; rates higher in children &#x0003c;1 years of age and those who received irradiation [12% vs 7%]).</i></div></div></li><li><div class="bk_ref" id="VincaAlkaloids.REF.ortega.1997.2435">Ortega JA, Donaldson SS, Ivy SP, Pappo A, Maurer HM. Venoocclusive disease of the liver after chemotherapy with vincristine, actinomycin D, and cyclophosphamide for the treatment of rhabdomyosarcoma. A report of the Intergroup Rhabdomyosarcoma Study Group. Childrens Cancer Group, the Pediatric Oncology Group, and the Pediatric Intergroup Statistical Center. <span><span class="ref-journal">Cancer. </span>1997;<span class="ref-vol">79</span>:2435–9.</span> [<a href="/pubmed/9191535" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9191535</span></a>]<div><i>(Among 821 children [ages 2 to 15 years] with rhabdomyosarcoma treated with vincristine, dactinomycin and cyclophosphamide, 10 [1.2%] developed SOS and 1 died; single major risk factor was higher doses of cyclophosphamide).</i></div></div></li><li><div class="bk_ref" id="VincaAlkaloids.REF.nishihori.2000.1231">Nishihori Y, Yamauchi N, Kuribayashi K, Sato Y, Morii K, Hirayama Y, Sakamaki S, et al.  <span><span class="ref-journal">Rinsho Ketsueki. </span>2000;<span class="ref-vol">41</span>:1231–7.</span> [Severe hemolysis and SIADH-like symptoms induced by vincristine in an ALL patient with liver cirrhosis] Japanese. [<a href="/pubmed/11193445" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11193445</span></a>]<div><i>(Abstract only: 11 year old boy with leukemia and chronic hepatitis C developed severe hemolysis and died of hepatic failure while being treated with vincristine).</i></div></div></li><li><div class="bk_ref" id="VincaAlkaloids.REF.van_der_hul.2003.153">van der Hul RL, Seynaeve C, van Geel BN, Verweij J. Low dose methotrexate and vinblastine, given weekly to patients with desmoid tumours, is associated with major toxicity. <span><span class="ref-journal">Sarcoma. </span>2003;<span class="ref-vol">7</span>:153–7.</span> [<a href="/pmc/articles/PMC2395524/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2395524</span></a>] [<a href="/pubmed/18521380" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18521380</span></a>]<div><i>(Among 10 patients with desmoid tumors given methotrexate [50 mg/week] and vinblastine [10 mg/week], severe side effects were common and 2 developed transient ALT elevations [3 to 10 times ULN] without jaundice).</i></div></div></li><li><div class="bk_ref" id="VincaAlkaloids.REF.arndt.2004.1894">Arndt C, Hawkins D, Anderson JR, Breitfeld P, Womer R, Meyer W. Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide. <span><span class="ref-journal">J Clin Oncol. </span>2004;<span class="ref-vol">22</span>:1894–901.</span> Erratum in: J Clin Oncol 2004; 22: 3434. [<a href="/pubmed/15143082" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15143082</span></a>]<div><i>(Among 339 children with rhabdomyosarcoma treated with vincristine, dactinomycin and cyclophosphamide, 18 [6%] developed hepatotoxicity and 3 died [1%]; risk of liver injury was greater in children &#x0003c;3 years of age [15% vs 4%]).</i></div></div></li><li><div class="bk_ref" id="VincaAlkaloids.REF.reuben.2010.2065">Reuben A, Koch DG, Lee WM., Acute Liver Failure Study Group.  Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. <span><span class="ref-journal">Hepatology. </span>2010;<span class="ref-vol">52</span>:2065–76.</span> [<a href="/pmc/articles/PMC3992250/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3992250</span></a>] [<a href="/pubmed/20949552" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20949552</span></a>]<div><i>(Among 1198 patients with acute liver failure enrolled in a US prospective study between 1998 and 2007, 133 were attributed to drug induced liver injury and 2 to antineoplastic agents [melphalan and gemtuzumab], but none to vincristine or vinblastine).</i></div></div></li><li><div class="bk_ref" id="VincaAlkaloids.REF.ferrajolo.2010.721">Ferrajolo C, Capuano A, Verhamme KM, Schuemie M, Rossi F, Stricker BH, Sturkenboom MC. Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase. <span><span class="ref-journal">Br J Clin Pharmacol. </span>2010;<span class="ref-vol">70</span>:721–8.</span> [<a href="/pmc/articles/PMC2997312/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2997312</span></a>] [<a href="/pubmed/21039766" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21039766</span></a>]<div><i>(Worldwide pharmacovigilance database contains 9036 hepatic adverse drug reactions in children; vincristine accounted for 46 instances, ranking 26th).</i></div></div></li><li><div class="bk_ref" id="VincaAlkaloids.REF.langholz.2011.252">Langholz B, Skolnik JM, Barrett JS, Renbarger J, Seibel NL, Zajicek A. Arndt CAs. Dactinomycin and vincristine toxicity in the treatment of childhood cancer: a retrospective study from the Children's Oncology Group. <span><span class="ref-journal">Pediatr Blood Cancer. </span>2011;<span class="ref-vol">57</span>:252–7.</span> [<a href="/pmc/articles/PMC3467305/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3467305</span></a>] [<a href="/pubmed/21671362" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21671362</span></a>]<div><i>(Retrospective review of six pediatric cancer clinical trials, comprising 4567 patients; the review found an overall risk for hepatotoxicity due to dactinomycin to be between 10-15%, depending upon age and type of tumor being treated; patients &#x0003c;1 year of age were at greater hepatotoxicity risk; vincristine was not associated with liver injury in this review).</i></div></div></li><li><div class="bk_ref" id="VincaAlkaloids.REF.bj_rnsson.2013.1419">Bj&#x000f6;rnsson ES, Bergmann OM, Bj&#x000f6;rnsson HK, Kvaran RB, Olafsson S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. <span><span class="ref-journal">Gastroenterology. </span>2013;<span class="ref-vol">144</span>:1419–25.</span> [<a href="/pubmed/23419359" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23419359</span></a>]<div><i>(In a population based study of drug induced liver injury from Iceland, 96 cases were identified over a 2 year period, none of which were attributed to a vinca alkaloid).</i></div></div></li><li><div class="bk_ref" id="VincaAlkaloids.REF.hern_ndez.2014.231">Hern&#x000e1;ndez N, Bessone F, S&#x000e1;nchez A, di Pace M, Brahm J, Zapata R, A, Chirino R, et al.  Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports. <span><span class="ref-journal">Ann Hepatol. </span>2014;<span class="ref-vol">13</span>:231–9.</span> [<a href="/pubmed/24552865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24552865</span></a>]<div><i>(Systematic review of literature of drug induced liver injury in Latin American countries published from 1996 to 2012 identified 176 cases, none of which were attributed to a vinca alkaloid).</i></div></div></li><li><div class="bk_ref" id="VincaAlkaloids.REF.chalasani.2015.1340">Chalasani N, Bonkovsky HL, Fontana R, Lee W, Stolz A, Talwalkar J, Reddy KR, et al. United States Drug Induced Liver Injury Network.  Features and outcomes of 899 patients with drug-induced liver injury: The DILIN Prospective Study. <span><span class="ref-journal">Gastroenterology. </span>2015;<span class="ref-vol">148</span>:1340–52.e7.</span> [<a href="/pmc/articles/PMC4446235/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4446235</span></a>] [<a href="/pubmed/25754159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 25754159</span></a>]<div><i>(Among 899 cases of drug induced liver injury enrolled in a US prospective study between 2004 and 2013, 363 [36%] were attributed to antibiotics, only one of which was attributed to a vinca alkaloid, vincristine in a 42 year old woman with HIV infection and lymphoma treated with combination chemotherapy and developing jaundice within a few weeks, bilirubin rising to 17.9, ALT 82 U/L, Alk P 265 U/L; resolving and later tolerating the other drugs in the combination).</i></div></div></li><li><div class="bk_ref" id="VincaAlkaloids.REF.wang.2017.4657">Wang J, Zheng R, Wang Z, Yang Y, Wang M, Zou W. Efficacy and safety of vinorelbine plus cisplatin vs. gemcitabine plus cisplatin for treatment of metastatic triple-negative breast cancer after failure with anthracyclines and taxanes. <span><span class="ref-journal">Med Sci Monit. </span>2017;<span class="ref-vol">23</span>:4657–64.</span> [<a href="/pmc/articles/PMC5629993/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5629993</span></a>] [<a href="/pubmed/28957036" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28957036</span></a>]<div><i>(Among 48 patients with refractory metastatic breast cancer treated with cisplatin combined with either vinorelbine or gemcitabine, objective response rates were similar [46%], as was time to progression and adverse events; mild [grade 1 or 2] &#x0201c;hepatic dysfunction&#x0201d; arose in 27% of both groups and did not require dose modification or progress to clinically apparent liver injury).</i></div></div></li><li><div class="bk_ref" id="VincaAlkaloids.REF.eslami.2018.bcr2018225474">Eslami A, Mathur AD, Jha KK, Wang H. Acute liver failure secondary to ABVD use. <span><span class="ref-journal">BMJ Case Rep. </span>2018;<span class="ref-vol">2018</span>:bcr2018225474. </span> [<a href="/pmc/articles/PMC6067149/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6067149</span></a>] [<a href="/pubmed/30061135" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30061135</span></a>]<div><i>(79 year old woman with Hodgkin disease was found unconscious 3 hours after completing a first cycle of ABVD [doxorubicin, bleomycin, vinblastine and dacarbazine], with liver injury arising over the next 24 hours [bilirubin 2.6 mg/dL on day 2, ALT 980 U/L, Alk P 126, lactate 5.3 mmol/L], with rapid recovery).</i></div></div></li><li><div class="bk_ref" id="VincaAlkaloids.REF.tanoshima.2019.356">Tanoshima R, Khan A, Biala AK, Trueman JN, Dr&#x000f6;gem&#x000f6;ller BI, Wright GEB, Hasbullah JS, et al. Canadian Pharmacogenomics Network for Drug Safety Consortium.  Analyses of adverse drug reactions-nationwide active surveillance network: Canadian Pharmacogenomics Network for Drug Safety Database. <span><span class="ref-journal">J Clin Pharmacol. </span>2019;<span class="ref-vol">59</span>:356–63.</span> [<a href="/pubmed/30452777" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30452777</span></a>]<div><i>(Among 10,475 adverse drug reaction reports made to a Canadian pharmacovigilance registry between 2005 and 2017 from 26 medical centers, 73% were pediatric and the most commonly implicated drugs were antineoplastic agents, including methotrexate, vincristine, doxorubicin, cisplatin, L-asparaginase, cyclophosphamide, dexamethasone, cytarabine and etoposide, hepatotoxicity being the 10th most common type of reaction [194 cases]).</i></div></div></li><li><div class="bk_ref" id="VincaAlkaloids.REF.peng.2019.1119">Peng S, Yang K, Xu Z, Chen S, Ji Y. Vincristine and sirolimus in the treatment of kaposiform haemangioendothelioma. <span><span class="ref-journal">J Paediatr Child Health. </span>2019;<span class="ref-vol">55</span>:1119–24.</span> [<a href="/pubmed/30604513" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30604513</span></a>]<div><i>(Metaanalysis of trials of vincristine and sirolimus for Kaposiform hemangioendothelioma identified 5 studies in 75 patients of vincristine, with adverse event reports from 16 subjects, the most common events being neuropathy [38%], abdominal pain [19%], anorexia [6%] and transient ALT elevations [12%]; no mention of clinically apparent liver injury).</i></div></div></li><li><div class="bk_ref" id="VincaAlkaloids.REF.younes.2019.1285">Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, Patti C, et al. PHOENIX investigators.  Randomized phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal center B-cell diffuse large B-cell lymphoma. <span><span class="ref-journal">J Clin Oncol. </span>2019;<span class="ref-vol">37</span>:1285–95.</span> [<a href="/pmc/articles/PMC6553835/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC6553835</span></a>] [<a href="/pubmed/30901302" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30901302</span></a>]<div><i>(Among 838 patients with large B cell lymphoma treated with R-CHOP with or without ibrutinib, overall survival was not improved by ibrutinib, but serious side effects were greater [53% vs 34%]; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="VincaAlkaloids.REF.poeschel.2019.2271">Poeschel V, Held G, Ziepert M, Witzens-Harig M, Holte H, Thurner L, Borchmann P, et al. FLYER Trial Investigators.  German Lymphoma Alliance. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. <span><span class="ref-journal">Lancet. </span>2019;<span class="ref-vol">394</span>(10216):2271–81.</span> [<a href="/pubmed/31868632" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 31868632</span></a>]<div><i>(Among 592 patients with B cell non-Hodgkin lymphoma treated with 6 cycles of R-CHOP vs 4 cycles with 2 further cycles of rituximab alone, progression free survival was similar in the two groups while adverse events were more with the 6 cycles; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="VincaAlkaloids.REF.br_hwiler.2020.51">Br&#x000fc;hwiler LD, Schwappach DL. Safe vincristine use in Switzerland: still a long way to go? <span><span class="ref-journal">J Oncol Pharm Pract. </span>2020;<span class="ref-vol">26</span>:51–9.</span> [<a href="/pubmed/30866715" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 30866715</span></a>]<div><i>(The medical error of administration of vincristine intrathecally instead of intravenously leads to progressive decerebration and death within a few days, and international recommendations to prevent this error have not been rigorously adopted as shown by surveys of pharmaceutical services in Switzerland).</i></div></div></li><li><div class="bk_ref" id="VincaAlkaloids.REF.sehn.2020.71">Sehn LH, Martelli M, Trn&#x0011b;n&#x000fd; M, Liu W, Bolen CR, Knapp A, Sahin D, et al.  A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA. <span><span class="ref-journal">J Hematol Oncol. </span>2020;<span class="ref-vol">13</span>:71.</span> [<a href="/pmc/articles/PMC7276080/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC7276080</span></a>] [<a href="/pubmed/32505213" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 32505213</span></a>]<div><i>(Among 1414 patients with large B cell lymphoma treated with CHOP and either rituximab [R-CHOP] or obinutuzumab [G-CHOP] [both monoclonal antibodies to CD20], progression-free survival rates were similar [64% and 63%] as were total adverse events, but serious events were more frequent with G-CHOP [44% vs 38%]; no mention of ALT elevations or hepatotoxicity).</i></div></div></li><li><div class="bk_ref" id="VincaAlkaloids.REF.dalal.2020.1">Dalal M, Gupta J, Price K, Zomas A, Miao H, Ashaye A. Efficacy and safety of front-line treatments for advanced Hodgkin lymphoma: a systematic literature review. <span><span class="ref-journal">Expert Rev Hematol. </span>2020 Aug 4;:1–16.</span> Epub ahead of print. [<a href="/pubmed/32749937" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 32749937</span></a>]<div><i>(Systematic review of first line therapies of advance Hodgkin disease focused on ABVD [doxorubicin, bleomycin, vinblastine and dacarbazine] and BEACOPP [bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine and prednisone], discussing side effects of pulmonary toxicity, secondary malignancies, neutropenia and peripheral neuropathy but not hepatotoxicity or ALT elevations).</i></div></div></li></ul></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright Notice</a></div><div class="small"><span class="label">Bookshelf ID: NBK547989</span><span class="label">PMID: <a href="/pubmed/31643321" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">31643321</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/livertox/">Drug Records</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/livertox/Vilazodone/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/livertox/Vismodegib/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK547989&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK547989/?report=reader">PubReader</a></li><li><a href="/books/NBK547989/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK547989" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK547989" style="display:none" title="Cite this Page"><div class="bk_tt">LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.  Vinca Alkaloids. [Updated 2020 Sep 12].<span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK547989/pdf/Bookshelf_NBK547989.pdf">PDF version of this page</a> (141K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Bulk Download</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://ftp.ncbi.nlm.nih.gov/pub/litarch/29/31/" ref="pagearea=source-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Bulk download LiverTox data from FTP</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Overviews</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/intro/">Introduction</a></li><li><a href="/books/n/livertox/Causality/">Causality</a></li><li><a href="/books/n/livertox/ClinicalCourse/">Clinical Course</a></li><li><a href="/books/n/livertox/ClinicalOutcome/">Clinical Outcomes</a></li><li><a href="/books/n/livertox/ImmuneFeatures/">Immune Features</a></li><li><a href="/books/n/livertox/DrugCategory/">Likelihood Scale</a></li><li><a href="/books/n/livertox/Phenotypes_intro/">Phenotypes</a></li><li><a href="/books/n/livertox/Severity/">Severity Grading</a></li><li><a href="/books/n/livertox/CaseReport/">Writing a Case Report</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Support Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/livertox/">LiverTox Homepage</a></li><li><a href="/books/n/livertox/aboutus/">About LiverTox</a></li><li><a href="/books/n/livertox/editorsandreviewers/">Editors and Review Committee</a></li><li><a href="/books/n/livertox/alert/">Meetings and News</a></li><li><a href="/books/n/livertox/abbreviation/">Abbreviations Used</a></li><li><a href="/books/n/livertox/glossary/">Glossary</a></li><li><a href="/books/n/livertox/resource/">Information Resources</a></li><li><a href="/books/n/livertox/disclaimer/">User/Medical Advice Disclaimer</a></li><li><a href="/books/n/livertox/Contactus/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>OTHER REFERENCE LINKS</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/sites/entrez?cmd=search&amp;db=pubmed&amp;pubmedfilters=true&amp;term=vinca+alkaloids+AND+Human%5BMH%5D+AND+(jaundice/CI+OR+bile+duct+diseases/CI+OR+liver/DE+OR+liver+diseases/CI)+AND+(%221900/1/1%22%5BEDat%5D:%222999/12/31%22%5BEDat%5D)" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Recent References on Vinca Alkaloids: from PubMed.gov</a></li><li><a href="http://clinicaltrials.gov/ct2/results?term=vinca+alkaloids" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Trials on Vinca Alkaloids: from ClinicalTrials.gov</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4857266" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pcsubstance&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pcsubstance&amp;IdsFromResult=4857266" ref="log$=recordlinks">PubChem Substance</a><div class="brieflinkpop offscreen_noflow">Related PubChem Substances</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4857266" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/8639632" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine.</a><span class="source">[Biochemistry. 1996]</span><div class="brieflinkpop offscreen_noflow">Interaction of vinca alkaloids with tubulin: a comparison of vinblastine, vincristine, and vinorelbine.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lobert S, Vulevic B, Correia JJ. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Biochemistry. 1996 May 28; 35(21):6806-14. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29714145" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">The Biological Activity of the Novel Vinca Alkaloids 4-chlorochablastine and 4-chlorochacristine.</a><span class="source">[Curr Cancer Drug Targets. 2019]</span><div class="brieflinkpop offscreen_noflow">The Biological Activity of the Novel Vinca Alkaloids 4-chlorochablastine and 4-chlorochacristine.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Montag G, Stopper H, Ngo QA, Hintzsche H. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Curr Cancer Drug Targets. 2019; 19(3):222-230. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/30417784" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Effect of Vinca Alkaloids on the Expression Levels of microRNAs Targeting Apoptosis-related Genes in Breast Cancer Cell Lines.</a><span class="source">[Curr Pharm Biotechnol. 2018]</span><div class="brieflinkpop offscreen_noflow">Effect of Vinca Alkaloids on the Expression Levels of microRNAs Targeting Apoptosis-related Genes in Breast Cancer Cell Lines.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Mavrogiannis AV, Kokkinopoulou I, Kontos CK, Sideris DC. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Curr Pharm Biotechnol. 2018; 19(13):1076-1086. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24404355" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Vinca alkaloids.</a><span class="source">[Int J Prev Med. 2013]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Vinca alkaloids.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Moudi M, Go R, Yien CY, Nazre M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Int J Prev Med. 2013 Nov; 4(11):1231-5. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/29035832" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> New insights into Vinca alkaloids resistance mechanism and circumvention in lung cancer.</a><span class="source">[Biomed Pharmacother. 2017]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> New insights into Vinca alkaloids resistance mechanism and circumvention in lung cancer.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Zhang Y, Yang SH, Guo XL. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">Biomed Pharmacother. 2017 Dec; 96:659-666. Epub 2017 Nov 6.</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=31643321" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=31643321" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class="&#10;                        HTOn&#10;                    "><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2021-03-08T16:31:15-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@9.2&amp;Host=portal101&amp;ncbi_phid=CE88715C0468AF910000000002FD00DE&amp;ncbi_session=CE88715C04697A21_0765SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK547989%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK547989&amp;ncbi_domain=livertox&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK547989/&amp;ncbi_pagename=Vinca Alkaloids - LiverTox - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE88715C04697A21_0765SID /projects/books/PBooks@9.2 portal101 v4.1.r621975 Fri, Dec 18 2020 02:56:50 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4192745/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>